Biomedical Engineering Reference
In-Depth Information
56. Byron PR (1994) Compendial dry powder testing: USP perspectives. In: Byron PR, Dalby RN,
Farr SJ (eds) Respiratory drug delivery-IV. Interpharm Press, Buffalo Grove, IL, pp 153-162
57. Dunbar CA, Hickey AJ, Holzner P (1998) Dispersion and characterization of pharmaceutical
dry powder aerosols. KONA Powder Part 16:7-45
58. Kamiya A, Sakagami M, Hindle M, Byron PR (2004) Locating particle bounce in the next
generation impactor (NGI). In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (eds)
Respiratory drug delivery-IX. Davis Healthcare International Publishing, River Grove, IL, pp
869-871
59. Berg E, Svensson JO, Asking L (2007) Determination of nebulizer droplet size distribution: a
method based on impactor refrigeration. J Aerosol Med 20(2):97-104
60. Kamiya A, Sakagami M, Hindle M, Byron PR (2004) Aerodynamic sizing of metered dose
inhalers: an evaluation of the Andersen and next generation pharmaceutical impactors and
their USP methods. J Pharm Sci 93(7):1828-1837
61. Nasr MM, Allgire JF (1995) Loading effect on particle size measurements by inertial sampling
of albuterol metered dose inhalers. Pharm Res 12(11):1677-1681
62. Feddah MR, Davies NM (2003) Influence of single versus multiple actuations on the particle
size distribution of beclomethasone dipropionate metered-dose inhalers. J Pharm Pharmacol
55(8):1055-1061
63. Merrin C, Lee S, Needham M, Chambers F (2003) Evaluation of NGI performance with high
dose pMDIs, 14th edn, Drug delivery to the lungs-14. The Aerosol Society, London, pp
184-187
64. Copley M (2007) Understanding cascade impaction and its importance for inhaler testing. Copley
Scientific Ltd Technical Briefing, Available at: http://www.copleyscientiic.co.uk/documents/
ww/Understanding%20Cascade%20Impaction%20White%20Paper.pdf . Visited 10 Jan 2012
65. MSP Corporation (2007) NGI User's Guide. NGI-0170-6001, Revision C. Available at: http://
www.epag.co.uk/Download2.asp?DID=902 . Visited 10 Jan 2012
66. Mitchell JP (2006) Cleaning: a survey of members of the European Pharmaceutical Aerosol
Group (EPAG), 17th edn, Drug delivery to the lungs-XVII. The Aerosol Society, Edinburgh,
pp 197-199
67. Mitchell JP, Costa PA, Waters S (1987) An assessment of an Andersen Mark-II cascade impac-
tor. J Aerosol Sci 19(2):213-221
68. European Directorate for Quality of Medicines and Healthcare (EDQM) (2012) Preparations
for nebulisation. Section 2.9.44—European Pharmacopeia, Council of Europe, 67075
Strasbourg, France
69. Dolovich M, Rhem R (1998) Impact of oropharyngeal deposition on inhaled dose. J Aerosol
Med S1:S112-S121
70. Harris D, Chaudhry S, Chaudry I, Li S, Sequeira J, Wyka B (1996) Influence of entry-port
design on drug deposition in cascade-impactor from metered-dose inhalers. AAPS Annual
Meeting. AAPS Poster Session, 1996
71. Van Oort M, Downey B (1996) Cascade impaction of MDIs and DPIs: proposal of induction
port, inlet cone, and pre-separator lid designs for inclusion in general chapter <601> Pharm
Forum 22(2):2204-2210
72. US Pharmacopeial Convention (2010) Chapter 1601: Products for nebulization—characteriza-
tion tests. In Process Revision, Pharm Forum 36(2):534-538
73. Keil JC, Reshima K, Peart J (2006) Using and interpreting aerosol electrostatic data from the
electrical low pressure impactor. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (eds)
Respiratory drug delivery-2006. Davis Healthcare International Publishing, River Grove, IL,
pp 267-277
74. Peart J, Orban JC, McGlynn P, Redmon M, Sargeant CM, Byron PR (2002) MDI electrostat-
ics: valve and formulation interactions which really make a difference. In: Dalby RN, Byron
PR, Peart J, Farr SJ (eds) Respiratory drug delivery-VIII. Davis Healthcare International
Publishing, River Grove, IL, pp 223-230
75. Bagger-Jörgensen H, Sandell D, Lundbäck H, Sundahl M (2005) Effect of inherent variability
of inhalation products on impactor mass balance limits. J Aerosol Med 18(4):367-378
Search WWH ::




Custom Search